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http://dx.doi.org/10.1016/j.ccr.2013.02.019SUMMARYReceptor tyrosine kinases (RTK) are targets for anticancer drug development. To date, only RTK inhibitors
that block orthosteric binding of ligands and substrates have been developed. Here, we report the pharma-
cologic characterization of the chemical SSR128129E (SSR), which inhibits fibroblast growth factor receptor
(FGFR) signaling by binding to the extracellular FGFR domain without affecting orthosteric FGF binding. SSR
exhibits allosteric properties, including probe dependence, signaling bias, and ceiling effects. Inhibition by
SSR is highly conserved throughout the animal kingdom. Oral delivery of SSR inhibits arthritis and tumors
that are relatively refractory to anti-vascular endothelial growth factor receptor-2 antibodies. Thus, orally
active, extracellularly acting small-molecule modulators of RTKs with allosteric properties can be developed
and may offer opportunities to improve anticancer treatment.Significance
Receptor tyrosine kinases (RTK) represent key targets for anticancer drug development. Classic examples of RTK blockers
include antibodies inhibiting orthosteric ligand binding, but small molecules that bind the extracellular domain of RTKs
have traditionally not been considered because they are thought to be too small to competitively block binding of the much
larger polypeptide ligands.We identified a small-molecule chemical compound, SSR128129E (SSR), which inhibits fibroblast
growth factor receptor (FGFR) signaling through allosteric mechanisms after binding to the extracellular FGFR domain. Oral
delivery of SSR inhibits tumor growth and amplifies anti-angiogenic drug therapy. These results offer incentives to develop
orally active small-molecule RTK inhibitors with allosteric properties and opportunities for improved anticancer treatment.
Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc. 477
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An Allosteric FGFR Inhibitor Blocks Tumor GrowthINTRODUCTION
Cell-surface receptors represent key targets for drug develop-
ment. Historically, drug discovery programs have been domi-
nated by efforts to develop antagonists that compete for binding
with endogenous ligands at orthosteric sites. Drugs that bind
to allosteric sites, i.e., topographically distinct domains from
those used by orthosteric ligands (if the target is a receptor) or
substrates (if the target is an enzyme) that modulate a protein’s
activity, have been more difficult to identify. Recently, allosteric
modulators have been identified for ligand-gated ion channels,
G protein-coupled receptors (GPCRs), and kinases (Chahrour
et al., 2012;Connet al., 2009;Coxet al., 2011; Thaker et al., 2012).
Allosteric kinase inhibitors have been developed (Chahrour
et al., 2012), but an extracellularly acting small-molecule allo-
steric inhibitor of receptor tyrosine kinases (RTKs) is not avail-
able. Yet, this receptor superfamily is of immense biomedical
significance (Lemmon and Schlessinger, 2010). Furthermore,
allosteric drugs offer therapeutic advantages over traditional
orthosteric drugs, including greater safety and/or selectivity
(Christopoulos, 2002). Most drugs targeting RTKs are antibodies
against growth factor receptors that inhibit ligand binding or
receptor dimerization or are small molecules inhibiting tyrosine
kinase (TK) activity (Chung and Ferrara, 2011; Tvorogov et al.,
2010). However, it is becoming increasingly clear that formation
of receptor signaling complexes requires allosteric confor-
mational changes in the extracellular domain to position the TK
domains for signal transduction (Brozzo et al., 2012; Landgraf
et al., 2010). Whether small molecules can inhibit or modulate
RTK signaling by acting extracellularly remains unexplored.
Anti-angiogenic therapy would benefit from other RTK small-
molecule inhibitors. Vascular endothelial growth factor (VEGF)-tar-
geted agents prolong the survival of patients with cancer, but
their success is restricted by refractoriness, escape, and in some
models, increased metastasis (Bergers and Hanahan, 2008;
Ebos and Kerbel, 2011). Combinatorial delivery of anti-angiogenic
agents may help overcome these challenges (You et al., 2011).
Receptors for basic fibroblast growth factors (FGFs) are
attractive drug candidates (Daniele et al., 2012; Itoh and Ornitz,
2011). FGF receptor (FGFR) signaling has been implicated in
cancer, inflammation, and the escape of tumor vascularization
from VEGF inhibitor treatment (Ahmad et al., 2012; Beenken
and Mohammadi, 2009; Casanovas et al., 2005; Fischer et al.,
2007; Malemud, 2007; Turner and Grose, 2010; Wesche et al.,
2011). Nonetheless, the FGFR superfamily with its 18 ligands
and four receptors has received little attention for drug develop-
ment, partly because of redundancy (Beenken andMohammadi,
2009). Selective TK inhibitors (TKIs) of FGFRs have not been
clinically approved, and only broad-spectrum TKIs targeting
primarily VEGF receptors (VEGFRs) and, less potently, FGFRs
are available (Daniele et al., 2012; McDermott et al., 2005). This
study characterizes an orally active, extracellularly acting
small-molecule inhibitor of FGFRs.
RESULTS
Identification of SSR128129E
The compound SSR128129E (‘‘SSR’’; Figure 1A) was identified
in a high-throughput screen, designed originally to discover478 Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc.orthosteric FGFR inhibitors. In this screen, we used a scintilla-
tion proximity assay (SPA) assay to identify chemicals blocking
binding of 125I-FGF2 to the extracellular domain of FGFR1-
D1D2D3/Fc, the extracellular domain with 3 Ig-like domains
D1-3 coupled to a Fc-fragment. A 10- to 100-fold molar excess
of unlabeled FGF2 or anti-FGFR1 Fab (aFGFR1) inhibited
125I-FGF2 binding completely, indicating that the assay identi-
fies compounds inhibiting ligand binding via a competitive
(orthosteric) mechanism (not shown). SSR emerged from this
screen as a low-affinity antagonist (half maximal inhibitory
concentration [IC50]: 1.9 ± 1.4 mM).
Surprisingly, SSR was effective in the nanomolar range in
cellular assays. Because FGF2 affects endothelial cells (ECs)
in vitro, we used human umbilical venous endothelial cells
(HUVECs) that express FGFR1 and lower levels of FGFR2 and
FGFR4. SSR dose-dependently inhibited FGF2-induced EC
proliferation (IC50: 31 ± 1.6 nM; Figure 1B), migration (IC50:
15.2 ± 4.5 nM; Figure 1C), and lamellipodia formation (Figure S1A
available online). Thus, SSR inhibited EC responses with nano-
molar potency, yet antagonized FGF binding only at micromolar
levels. This puzzling result suggested that SSR was not acting
as a classic orthosteric inhibitor and/or that its pharmacology
was highly sensitive to the cellular environment and confor-
mational properties of intact FGFR. We thus characterized its
pharmacological properties.
SSR Is a Multi-FGFR Inhibitor
We investigated if SSR blocked the response to other FGFs,
known to bind selectively to distinct FGFR subtypes. We there-
fore used cells from different species, expressing one or more
FGFRs, and stimulated them with various FGF ligands. SSR
inhibited responses mediated by FGFR1-4. For instance, SSR
blocked EC migration in response to FGF1, a ligand of FGFR1
and FGFR4 (Figure 1C), and capillary tube formation in response
to FGF19, a ligand of FGFR4 (Figure S1B). Proliferation and
migration of the murine pancreatic Panc02 tumor cell line in
response to FGF7 were also blocked by SSR (Figures 1D and
1E), showing that SSR inhibits FGFR subtypes of other species
as well. Table 1 lists the nanomolar potency activities of SSR
in blocking different FGFR subtypes in various cell lines used
to analyze migratory, mitogenic, and other responses to FGF
ligands. Notably, SSR inhibited FGFR paralogues in various
species across the animal kingdom, including Danio rerio
(zebrafish) (Figures S1C–S1F), Drosophila melanogaster (fruit
fly) (FiguresS1G-S1I),Spodoptera frugiperda (moth) (FigureS1J),
and Bombyx mori (silkworm) (not shown).
The effect of SSR was not due to nonspecific toxicity because
SSR (1 mM) failed to affect the mitogenic response to other
stimuli of B9 myeloma cells or L6 myoblasts, which did not
express FGFRs (not shown). Heparin (30 mg/ml) did not alter
the inhibitory activity of SSR on the mitogenic or chemotactic
response of FGFs (not shown).
SSR Inhibits FGFRs but Not Other Related RTKs
We then determined if SSR blocked the FGFR superfamily
selectively. SSR did not affect responses to ligands activating
structurally related RTKs (Figures 1E, 1F, and S1K). When
FGF7 and VEGF were added together to test the migration
of Panc02 tumor cells, SSR only blocked the response to
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Figure 1. Activity and FGFR Specificity of SSR
(A) Chemical structure of SSR128129E (SSR).
(B) Effect of SSR on FGF2-induced EC proliferation.
(C) Effect of SSR (100 nM) on FGF1-driven EC migration (n = 3; *p < 0.05 versus control, #p < 0.05 versus FGF1 alone).
(D) Effect of SSR (100 nM) on FGF7-driven proliferation of Panc02 tumor cells (n = 3; *p < 0.05 versus control, #p < 0.05 versus FGF7 alone).
(E) Effect of SSR (100 nM) on migration of Panc02 tumor cells in response to single or combined stimulation with FGF7 and VEGF (n = 3; *p < 0.05 versus control,
#p < 0.05 versus indicated condition).
(F) Effect of SSR (1 mM) on migration of ECs in response to different growth factors (n = 3; *p < 0.05 versus control, #p < 0.05 versus indicated condition). Data are
presented as mean ± SEM.
See also Figure S1 and Tables S1 and S2.
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An Allosteric FGFR Inhibitor Blocks Tumor GrowthFGF7 (Figure 1E). Similar results were obtained for the responses
of ECs to VEGF plus FGF1 (not shown) or to VEGF plus
FGF2 (Figure S1L), or of Panc02 cell responses to VEGF plus
FGF7 (not shown). Genetic experiments in zebrafish to silence
both fgfr1 and fgfr2 showed that SSR recapitulated quantita-
tively and qualitatively the phenotypic pharyngeal arch and
cartilage defects, induced by combined silencing of fgfr1 and
fgfr2, underscoring that SSR is a multi-FGFR inhibitor (Fig-
ures S1M–S1T). SSR failed however to induce additional
anomalies in zebrafish embryos lacking multiple FGFRs,
showing that SSR specifically inhibited multiple FGFRs in an
intact animal model without causing off-target effects (Figures
S1U and S1V).
In contrast to a 10- or 100-fold molar excess of a neutralizing
competitor or antibody, SSR failed to inhibit binding of VEGF,
VEGF-B, placental growth factor, platelet-derived growth factor
(PDGF)-BB, or PDGF-CC to their receptors, whose extracellular
domains exhibit the highest homology to FGFRs. SSR also failed
to inhibit phosphorylation of VEGFR2 or hepatocyte growth
factor-receptor MET (Figures S1W and S1X; Table S1). SSR
also did not alter receptor binding of interleukin-8, transforming
growth factor-b, tumor necrosis factor-a, or epidermal growth
factor, which are structurally more divergent from FGFs (Table
S2). SSR also did not inhibit binding of >100 distinct ligands
with related structural homology or entirely different chemical
composition from FGFs, even when used at concentrations up
to 10 mM (Table S2). Overall, SSR inhibited FGFR-driven
responses while not affecting other related RTKs.SSR Is Not a Potent Inhibitor of Orthosteric FGF Binding
to FGFR
We then aimed at determining SSR’s pharmacologic mecha-
nism. The weak inhibition of the binding of 125I-FGF2 to
FGFR1-D1D2D3/Fc in the scintillation proximity assay (SPA)
could be reconciled with a low-affinity orthosteric interaction or
a low-affinity allosteric interaction exhibiting negative binding
cooperativity (Christopoulos and Kenakin, 2002). However,
such modest effects on the binding affinity of 125I-FGF2 alone
could not explain the greater potency of SSR in assays of cellular
function. This would require a difference in binding affinity of
SSR at the intact receptor expressed in a native environment
and/or an allosteric effect on signal transduction (in addition
to any negative cooperativity on orthosteric agonist binding).
To address these possibilities, we determined the potency of
SSR as an inhibitor of the binding of 125I-FGF2 to FGFRs when
expressed in their native configuration in natural conditions on
the EC surface. Under these conditions, the potency of SSR
was reduced even more than in the SPA such that it was unable
to inhibit 125I-FGF2 binding to its receptors even at high
micromolar concentrations (Figure 2A). In contrast, orthosteric
inhibitors such as unlabeled FGF2, a neutralizing anti-FGF2
antibody or anti-FGFR1 (aFGFR1) blocked 125I-FGF2 binding
(Figure 2A). Thus, in this cellular binding assay, SSR did not
act as a strong orthosteric inhibitor. Such contextual assay-
dependent results are inconsistent with a simple competitive
mechanism that relies on steric hindrance for an overlapping
binding domain because the latter would yield consistentCancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc. 479
Table 1. Effects of SSR onCellular Responses to Different FGFRs
FGF
Receptor
FGF
Ligand Cell Line
Cellular
Assay
SSR Concentration
Resulting inR50%
Inhibitiona
FGFR1IIIca FGF1 PAE-hFGFR1 Proliferation 100 nMb
FGF2 PAE-hFGFR1 Proliferation 100 nMb
FGFR1IIIcb FGF1 HUVEC Proliferation,
migration
100 nMb
FGF2 HUVEC Proliferation,
migration,
survival
15–22 nM
FGF4 HUVEC Proliferation,
migration
100 nMb
FGFR2IIIca FGF2 HEK-
hFGFR2WT
ERK
activation
28 nM
FGFR2IIIb FGF7 mPanc02 Proliferation,
migration
100 nMb
FGFR3IIIca FGF1 hB9-
myeloma
Proliferation 25 nMb
FGFR4IIIca FGF2 HUVEC Proliferation,
migration,
survival
15–22 nM
FGF19 HUVEC Tube
formation
10 nMb
PAE, porcine aortic endothelial cells.
aIC50 value of SSR (nM) determined by using various concentrations.
bOnly two or three concentrations of SSR were tested without deter-
mining the precise IC50 value; in these cases, the indicated concentration
already resulted in >50% inhibition.
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An Allosteric FGFR Inhibitor Blocks Tumor Growthinhibition of binding in all assays (as observed for unlabeled
FGF2, aFGF2, and aFGFR1). Rather, these findings are charac-
teristic of small-molecule allosteric modulators of other receptor
classes that exert minimal effects on orthosteric ligand affinity
(i.e., low negative cooperativity in the case of FGFR1-D1D2D3/
Fc or neutral cooperativity in the case of intact FGFR) but have
profound effects on orthosteric ligand signaling (Litschig et al.,
1999). Indeed, the ability to mediate differential effects on the
binding and function of orthosteric ligands in an assay-depen-
dent manner is a typical feature of allosteric receptor modu-
lators, referred to as ‘‘probe dependence’’ (Christopoulos and
Kenakin, 2002; Litschig et al., 1999; Price et al., 2005).
Pharmacological Validation of an Allosteric Mechanism
for SSR
SSR’s inhibitory activity on FGFR signaling was not due to inhi-
bition of dimerization of FGF receptors or ligands (Herbert
et al., 2013). We thus used ECs and HEK293 cells stably ex-
pressing FGFR1 or FGFR3, respectively, to study whether SSR
reduced FGFR phosphorylation in response to FGF1. FGFR
immunoprecipitation, followed by blotting for phosphotyrosine,
revealed that FGFR tyrosine phosphorylation in response to
FGF1 was reduced by nanomolar SSR concentrations (Figures
2B and 2C). We thus explored if inhibition by SSR of FGFR-TK
activity was consistent with an allosteric mechanism. At least
four characteristic features of allosteric antagonists have been
identified for other classes of cell-surface receptors, including:
(1) the ability to act at a topographically distinct site away from480 Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc.orthosteric or substrate-binding sites; (2) the ability to display
‘‘probe dependence’’ (see above); (3) a saturability, or ceiling
level, to the allosteric effect, above which no further antagonism
is observed irrespective of ligand concentration; and (4) different
degrees of inhibition depending on the signal pathway that is
being modulated, a phenomenon referred to as ‘‘pathway
bias’’ (Keov et al., 2011).
SSR Interacts with a Topographically Distinct Site
FGFR-TKIs, which competitively block binding of ATP to its
orthosteric site in the TK domain, must cross the plasma
membrane. High-performance liquid chromotography analysis
indicated that lysates of cells treated with 10 mM SSR contained
only background traces of SSR (Figure S2), indicating that
SSR failed to cross the plasma membrane and did not accu-
mulate at high levels intracellulary. Calculation by theoretical
prediction of the octanol-water partition coefficient (theoretical
LogPOW: 2.018), a measure of the lipophilicity of the com-
pound, also showed that SSR was preferentially distributed in
a hydrophilic rather than hydrophobic milieu and thus unlikely
to cross the plasma membrane.
Use of a recombinant FGFR1-TK domain revealed that even
supraphysiologic concentrations of SSR failed to inhibit the TK
activity in contrast to the FGFR-TK inhibitor SU5402 (Figure 2D).
We also used B9 myeloma cells because they express a con-
stitutively active FGFR3K650E mutant, which stimulates cell pro-
liferation in the absence of FGF. If SSR would be cell permeable
and inhibit TK, then SSR should block the growth of FGFR3K650E
cells. In cells expressing wild-type FGFR3 (FGFR3WT), FGF1
enhanced proliferation and this response was reduced by SSR
(Figure 2E). As expected, FGF1 failed to further stimulate growth
of FGFR3K650E cells, while SSR was ineffective in reducing con-
stitutively activated proliferation (Figure 2E). In contrast, SU5402
inhibited proliferation of both FGFR3WT and FGFR3K650E ex-
pressing B9 cells (Figure 2E).
Given that SSR indirectly blocked the FGFR-TK activity yet
failed to cross the plasma membrane, we analyzed if SSR
interacted with the extracellular domain of FGFR. We purified
FGFR2-D2D3, a fragment of the extracellular domain of FGFR2
consisting of domain D2 and D3, and used mass spectrometry
to determine if SSR bound to this fragment. Spectral analysis
showed the predicted mass of FGFR2-D2D3 when measured
in the absence of SSR (Mr = 24,493 Da) and revealed that the
mass was augmented in the presence of a 10-fold molar excess
of SSR by 322 Da, e.g., the molecular weight of SSR without
Na+ and H2O (Figure 3A). This indicates that SSR binds with
a stoichiometry of n = 1 to FGFR2-D2D3. SSR did not bind to
FGFR2-D2L, consisting of D2 plus adjacent linker, indicating
that SSR binds to D3 (Figure 3B). Because FGFR2-D2L contains
the binding pocket for FGF, the lack of binding of SSR to
FGFR2-D2L also supports our finding that SSR is unable to
block orthosteric FGF binding. As negative control, no binding
of SSR to FGF1 was detected (not shown), consistent with
nuclear magnetic resonance studies (Herbert et al., 2013).
SSR Displays a Ceiling Level to Its Antagonism of FGFR
Phosphorylation
SSR (100 nM) reduced tyrosine phosphorylation of FGFR1
and FGFR3 (see above). Remarkably, even a supramaximal
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Figure 2. Mode of Action of SSR: Binding
and Phosphorylation Assays
(A) Binding of 125I-FGF2 to porcine aortic ECs
(PAE) overexpressing FGFR1 with and without
the orthosteric inhibitors anti-FGF2 (aFGF2) or
anti-FGFR1 Fab (aFGFR1), or a 100-fold molar
excess of SSR (100 mM). Data are corrected
for residual background binding in the presence
of 100-fold molar excess of unlabeled FGF2
(n = 3; *p < 0.05).
(B) Immunoblotting with densitometric quantifi-
cation of FGF1-induced tyrosine phosphorylation
of FGFR1 in ECs in the absence or presence
of SSR.
(C) Immunoblotting with densitometric quantifi-
cation of FGF1-induced phosphorylation of wild-
type FGFR3 in HEK293 cells in the absence or
presence of SSR.
(D) Effect of SSR in a phosphorylation assay
using the isolated kinase domain of FGFR1. The
RTKI SU5402 was used as positive control (n = 3;
*p < 0.05).
(E) Effect of SSR on FGF1-induced proliferation
of B9 myeloma cells expressing FGFR3WT or the
constitutively active FGFR3K650E mutant. The RTKI
SU5402 was used as positive control (n = 3; *p <
0.05). Ctrl, control vehicle (DMSO). Quantitative
data are presented as mean ± SEM.
See also Figure S2.
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An Allosteric FGFR Inhibitor Blocks Tumor Growthconcentration of SSR (10 mM) did not completely eliminate FGFR
but left a residual level of FGFR autophosphorylation (Figures 2B
and 2C). This phenomenon cannot be reconciled with a compet-
itive orthosteric mechanism and is another hallmark of allosteric
interactions, namely a ‘‘ceiling level’’ to the actions of the allo-
steric modulator, above which no further pharmacologic effect
is observed irrespective of modulator concentration (Conn
et al., 2009; May et al., 2007). These findings suggest a limited
negative cooperativity on FGFR signaling, in essence ‘‘tuning
down’’ the degree of autophosphorylation to a new (lower) set-
point. Similar data were obtained when analyzing tyrosine phos-
phorylation of FGFR1 and FGFR2 in HEK293 cells in response
to FGF1 or FGF2 (not shown). We also analyzed the effect of
increasing concentrations of SSR on the mitogenic response
to different concentrations of FGF2, showing a shift to the right
with increased sigmoidicity of the curve (Figure 3C), another
hallmark of allostery (Christopoulos, 2002). This observation is
comparable to effects observed for the allosteric antagonist 7-
hydroxyimino-cyclopropan[b]chromen-1a-carboxylic acid ethyl
ester of glutamate receptor 1 (Knoflach et al., 2001).
SSR Displays Pathway-Biased Antagonism of FGFR
Signaling
Based on studies of allosteric modulators for other receptor
classes, there is no a priori reason why conformational changes
resulting from binding of the allosteric modulator should display
equivalent degrees of allosteric modulation across different
signaling pathways, if the allosteric interaction predominantlyCancer Cell 23, 477–4modulates orthosteric ligand efficacy
rather than affinity (Leach et al., 2007)—
a phenomenon referred to as ‘‘functionalselectivity’’, ‘‘stimulus-trafficking’’, or ‘‘biased antagonism’’
(Urban et al., 2007). To assess if SSR induced biased antago-
nism, we generated a phosphomap of two major FGFR signaling
pathways, i.e., FRS2-ERK1/2 and PLC-g (Beenken and Moham-
madi, 2009).
In FGFR2-expressing HEK293 cells (HEK-FGFR2), levels of
phosphorylated FRS2 (pFRS2) and ERK1/2 (pERK1/2) were
minimal in baseline and upregulated by FGF2 (Figures 3D and
3E). SSR and the pan-FGFR-TKI SU5402 inhibited phosphory-
lation of FRS2 and ERK1/2 (Figures 3D and 3E). However, unlike
SU5402, SSR did not eliminate all FRS2 and ERK1/2 phosphor-
ylation, in line with SSR’s ceiling effect. Higher concentrations
of FGF2 could not overcome the inhibition of ERK1/2 phosphor-
ylation by SSR, further supporting the ceiling phenomenon
(not shown). In the same cells, FGF2 elevated the levels of
phosphorylated PLC-g (pPLC-g) (Figure 3F). In contrast to its
inhibitory effect on FRS2 and ERK1/2, activation of PLC-g was
not blocked by SSR at the concentration (1 mM) that inhibited
FRS2/ERK phosphorylation (Figure 3F). This induction of
pPLC-g was fully blocked by SU5402 (Figure 3F). Thus, SSR
does not inhibit all FGFR signaling pathways indiscriminatively
but selectively blocks particular signaling pathways, dependent
on the cellular context. This biased antagonism of a RTK by
a small molecule interacting with the extracellular domain can
only be achieved via an allosteric mechanism. Collectively, our
pharmacologic studies show that SSR exhibits all characteristic
features of a small-molecule allosteric receptor inhibitor of
FGF-driven cellular processes in vitro.88, April 15, 2013 ª2013 Elsevier Inc. 481
FGFR2-D2D3
A
FGFR2-D2D3
+ SSR
24493
24815
100
80
60
40
20
0
24500 24700
re
la
tiv
e 
in
te
ns
ity
 (%
)
(Da)
B
FGFR2-D2+L
100
80
60
40
20
0
13000 13200 (Da)
re
la
tiv
e 
in
te
ns
ity
 (%
)
13024
pERK1/2
ERK1/2
- + ++
- - -+
- - +-
E
FGF2
SSR (1 μM)
SU5402 (1 μM)
pPLC-γ
PLC-γ
- + ++
- - -+
- - +-
F
FGF2
SSR (1 μM)
SU5402 (1 μM)
D
FGF2
SSR (1 μM)
- + ++
pFRS2
FRS2
SU5402 (1 μM)
- - -+
- - +-
pr
ol
ife
ra
tio
n
(%
 th
ym
id
in
e 
in
co
rp
or
at
io
n)
ctrl100
50
0
log  [FGF2] 
-1.5 0.5-1.0 -0.5 0.0
C
30 nM SSR
100 nM SSR
(ng/mL)
Figure 3. SSR-FGFR Binding Spectra and
Effect on FGF-Signaling Pathways
(A and B) Spectra analysis of SSR binding to re-
combinant extracellular domain fragments of
FGFR2. (A) The highest peak on the left corre-
sponds to the expected molecular mass of the
FGFR2-D2-3 fragment (24,493 Da); the peak on
the right corresponds to the mass of FGFR2-D2-3
plus a single molecule of SSR (24,815 Da). (B) The
highest peak corresponds to the expected
molecular mass of FGFR2-D2L (13,024 Da).
(C) Effect of increasing SSR concentrations on the
mitogenic response of ECs to increasing FGF2
concentrations. Ctrl, control vehicle (DMSO).
Quantitative data are presented as mean ± SEM.
(D–F) Immunoblots for FGF2-induced tyrosine
phosphorylation of FRS2 (D), ERK1/2 (E), or PLC-g
(F) in the absence or presence of SSR. The RTKI
SU5402 was used as positive control.
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An Allosteric FGFR Inhibitor Blocks Tumor GrowthSSR Inhibits Angiogenesis, Inflammation, and Bone
Resorption in Arthritis
We then explored if SSR is capable of inhibiting inflammatory
andmalignant diseases, known as FGFR-driven processes (Mal-
emud, 2007). Oral administration of SSR (30 mg/kg/day from
day 3 onward; unless otherwise specified) reduced the number
of limbs affected by redness, swelling, and deformity (3.6 ± 0.1
in controls versus 1.2 ± 0.1 after SSR; n = 10–14; p < 0.001).
SSR reduced the severity of clinical symptoms (Figures 4A–4C)
and slowed down its progression (day of maximal clinical score:
12.7 ± 0.3 days in controls versus 15.3 ± 0.8 days after SSR;
n = 10; p < 0.01). Radiography revealed that SSR protected
the mice against bone and joint damage (Figures 4D and 4E).
SSR-treated mice also performed better in an exercise endur-
ance test and ran longer on a treadmill (Figure 4F).
SSR reduced angiogenesis in the inflamed joints (CD31+
vessels per optic field: 3.4 ± 1.6 in normal joints; 28.6 ± 4.2 in
arthritic joints of controls versus 11.9 ± 4.6 in arthritic joints
after SSR; n = 10–18; p < 0.05; Figures 4G and 4H). The anti-
angiogenic activity of SSR was confirmed in a matrigel model
(hemoglobin content: 57 ± 10 mg/ml in control versus 12 ±
3 mg/ml in SSR mice; n = 5; p < 0.05). SSR attenuated synovial
hyperplasia, inflammation, and pannus formation (Figures 4I,
4J,and 4M), and inhibited the infiltration of CD45+ leukocytes
(CD45+ area, percentage of synovial area after 1 week:
14.5% ± 2.3% in controls versus 7.2% ± 1.5% after SSR;
n = 5, p < 0.05) and osteoclast-mediated cartilage breakdown
(safranin-O+ area/mm: 12.1 ± 1.2 mm2 in controls versus 16.5 ±
2.2 mm2 after SSR; n = 18; p < 0.05; Figures 4K and 4L).
Oral SSR Delivery Delays Tumor Growth and Metastasis
We also analyzed if SSR inhibited tumor angiogenesis, growth,
and metastasis using syngeneic and orthotopic tumor models
and human xenograft tumor models. Oral delivery of SSR
(30 mg/kg/day, from day 3) inhibited growth of orthotopic
Panc02 tumors by 44% (Figures 5A, 5C, and 5E) and delayed
growth of Lewis lung carcinoma (LLC) (end-stage tumor size
and weight: 1,120 ± 120mm3 and 750 ± 80mg in controls versus
720 ± 133 mm3 and 430 ± 90 mg after SSR; n = 15; p < 0.05; Fig-
ure 5F). In murine 4T1 breast tumors, oral SSR (30 mg/kg/day,482 Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc.from day 5) reduced tumor size and weight by 53% and 40%,
respectively (end-stage tumor size and weight: 2,050 ±
172 mm3 and 840 ± 80 mg in controls versus 970 ± 127 mm3
and 510 ± 80 mg after SSR; n = 15; p < 0.001; Figure 5G). In
addition, SSR inhibited the growth of subcutaneous CT26
colon tumors by 34% (Figure 5H) and of the multidrug resistant
MCF7/ADR breast cancer xenograft model by 40% (end-stage
tumor volume: 250 ± 50 mm3 in controls versus 152 ± 25 mm3
after SSR; n = 15; p < 0.01). Tumor cells in these models ex-
pressed one or several FGFRs, while various FGF ligands were
also detectable (not shown).
SSR reduced tumor invasiveness because the incidences of
tumor invasion in healthy duodenum and of hemorrhagic ascites
were lower in SSR-treated mice (75% and 58% of controls
versus 15% and 8% of SSR-treated mice, respectively; n = 13;
p < 0.05). Moreover, SSR inhibited metastasis of Panc02 tumor
cells to peritoneal lymph nodes (metastatic nodules/mouse:
24 ± 2.6 in controls versus 8.3 ± 2.3 after SSR; n = 21; p <
0.05; Figures 5B and 5D). The reduced number of metastatic
lymph nodes upon SSR treatment was not attributable to
a reduction in tumor growth only because SSR decreased the
metastatic index (metastatic nodes/gram tumor: 41 ± 3 for
controls versus 30 ± 3 for SSR; n = 10; p < 0.05). In the LLC
model, SSR reduced the number of pulmonary metastatic
nodules by 43% after 3 weeks (lung metastases: 3.5 ± 0.3 in
control versus 2.0 ± 0.3 after SSR; n = 15; p < 0.05). Similar
results were obtained after orthotopic injection of 4T1 cells into
the mammary gland (metastases per lung: 12.7 ± 1.4 in control
versus 5.4 ± 0.4 after SSR; n = 15; p < 0.001). Altogether, SSR
inhibited both the growth of primary tumors and metastasis.
SSR Enhances Tumor Growth Inhibition by Anti-VEGFR2
A substantial fraction of patients with cancer do not or only
minimally respond to VEGFR inhibitor therapy (Ebos and Kerbel,
2011). Combinations of anti-angiogenic agents with com-
plementary mechanisms may offer opportunities to overcome
resistance. We therefore analyzed if SSR acts via a comple-
mentary mechanism to that of the anti-VEGFR2 antibody
DC101 (aVEGFR2) (Witte et al., 1998) and if delivery of SSR
enhanced the antitumor activity of aVEGFR2 using a model
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Figure 4. SSR Treatment of Inflammatory Joint Disease
(A) Clinical score of forelimbs and hindlimbs in arthritic mice treated with vehicle or SSR (30 mg/kg/day orally) (n = 10–14; p < 0.001 by repeated-measurement
ANOVA; *p < 0.05 versus control at each time point).
(B and C) Micrographs of forelimb of mice treated with vehicle (B) or SSR (C). Black arrows and arrowheads point to swelling and redness of wrist or digits,
respectively.
(D and E) X-ray images of forelimb of mice treated with vehicle (D) or SSR (E). White arrows: radiographic signs of aberrant bone formation; white arrowheads:
osteolytic lesions, bone fractures, and bone remodeling; open arrowheads: loss or remodeling of joint space; blue arrowheads: joint fusion.
(F) Endurance treadmill exercise of control and SSR-treated arthritic mice at day 20 after hypersensitization (n = 7–12; *p < 0.05).
(G and H) Immunostaining of synovial blood vessels (CD31; brown) in control (G) and SSR-treated mice (H).
(I and J) Hematoxylin and eosin staining to visualize synovial hyperplasia and inflammation in control (I) and SSR-treated mice (J). B, bone; I, synovial inflam-
mation; H, synovial hyperplasia.
(K and L) Safranin-O staining (red) of cartilage proteoglycans in control (K) and SSR-treated mice (L). Asterisks, the joint space; black arrowheads, presence of
erosive bone fragment.
(M) Histologic score of synovial hyperplasia, inflammation, and pannus formation in control and SSR-treated mice (n = 5–9. *p < 0.05 versus control by
Mann-Whitney). Scale bars: 100 mm (G–L). All quantitative data are presented as mean ± SEM.
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An Allosteric FGFR Inhibitor Blocks Tumor Growththat is more sensitive (Panc02 tumor) or more refractory (CT26
tumor) to VEGFR inhibitor therapy. In the Panc02 model, a low
dose of aVEGFR2 (5 mg/kg; three times per week) inhibited
tumor growth by 40% (Figure 5E), which is comparable to the
30% inhibition of tumor growth by a high dose of aVEGFR2
(50 mg/kg; three times per week; Figure 5H) in the CT26 model.
Mechanistically, both SSR and aVEGFR2 inhibited angiogen-
esis in Panc02 tumors (CD31+ area: 5.0% ± 0.4% in control;
3.8% ± 0.3% after SSR; 2.9% ± 0.3% after DC101; n = 10;
p < 0.05 for all treatments and for SSR versus aVEGFR2). SSR
differed however from aVEGFR2 in its effect on macrophage
infiltration. Indeed, in contrast to the lack of effect by aVEGFR2,
SSR inhibited inflammatory cell infiltration in tumors (Figures 5I–
5K). Similar findings were obtained for CT26 tumors (not shown).Thus, SSR inhibits tumor growth via mechanisms that differ from
those utilized by aVEGFR2.
We therefore tested if a combination of SSR plus aVEGFR2
inhibited Panc02 tumor growth more extensively. SSR and
aVEGFR2 each inhibited tumor growth by 40%, while the
combination treatment inhibited tumor growth by 70% (Fig-
ure 5E). Similar results were obtained when analyzing the
metastatic index (41% ± 3% for control; 30% ± 3% for SSR;
33% ± 3% for aVEGFR2 and 20% ± 1% for combination;
n = 10; p < 0.05 for all treatments and for SSR versus aVEGFR2).
When using the VEGFR inhibitor-refractory CT26 tumor model,
the combination treatment inhibited tumor growth more than
each monotherapy alone (Figure 5H). Thus, SSR acted via
different mechanisms from those used by the VEGFR2 inhibitor,Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc. 483
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Figure 5. SSR Treatment of Malignant
Disorders
(A–D) Effect of SSR (30 mg/kg/day orally) on
orthotopic pancreatic Panc02 tumor growth.
Representative images of the primary tumor
(dashed line) in a control (A) or SSR-treated mouse
(C). The white arrowhead in A denotes local
infiltration of the primary tumor in the stomach and
duodenum and a tumor-infiltrated celiac lymph
node. Representative images show tumor-in-
filtrated mesenterial lymph nodes (white arrow-
heads) in control (B) and SSR-treated mice (D).
(E) Effect of single and combined treatment of
orthotopically implanted Panc02 tumors with SSR
(30 mg/kg/day) or aVEGFR2 (5 mg/kg; three times
per week) on tumor weight as compared to
vehicle-treated tumors (8–10 mice per group, n =
3; *p < 0.05 versus control; xp < 0.05 versus either
monotherapy).
(F and G) Growth curve of subcutaneously im-
planted LLC tumors (F) and 4T1 breast tumors
(G), upon treatment with vehicle (control) or SSR
(30 mg/kg/day) (n = 3; *p < 0.05).
(H) Effect of single or combined treatment of
subcutaneously implanted CT26 colon tumors
with SSR (30 mg/kg/day) or aVEGFR2 (5 mg/kg;
three times per week intraperitoneally) on tumor
weight as compared to vehicle-treated tumors
(8–10 mice per group, n = 3; *p < 0.05 versus
control, xp < 0.05 versus either monotherapy).
(I–K) F4/80 immunostaining for macrophages in
tumors of SSR-treated (J) versus control (I) mice.
(K) shows quantification of tumor infiltration by
F4/80+ macrophages in SSR-treated compared to
control or aVEGFR2-treatedmice (n = 3; *p < 0.05).
All quantitative data are presented as mean ±
SEM. Scale bars: 100 mm (I, J).
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An Allosteric FGFR Inhibitor Blocks Tumor Growthinhibited growth of VEGFR inhibitor-refractory and -sensitive
tumor models, and enhanced the antitumor activity of a VEGFR
inhibitor.
Safety Profile
We assessed the safety profile of SSR by administering it to
healthy mice during 3 weeks (30 mg/kg/day). A therapeutic
dose of SSR did not cause vessel pruning (tracheal FITC+ vessel
area, percentage of total: 11.6% ± 1.1% in control versus
11.0% ± 0.6% after SSR; n = 6, p = NS), did not alter the mean
arterial blood pressure (86 ± 3 mm Hg in controls versus 91 ±
4 mm Hg after SSR; n = 5; p = NS), and only minimally elevated
plasma levels of the prothrombotic PAI-1 (1.0 ± 0.8 ng/ml in
control versus 2.7 ± 0.6 ng/ml in SSR-treated mice; n = 5, p <
0.05). Hematologic parameters were normal after SSR, except
for a minor anemia (red blood cells: 8.8 ± 0.1 106/ml in controls
versus 8.3 ± 0.1 106/ml after SSR; n = 5; p < 0.05). SSR did
also not significantly alter the body weight (21.2 ± 0.7 g in
controls versus 19.3 ± 1.0 g after SSR; p = NS). In addition, daily
treatment of Apo-E knockout mice with SSR for >6 months did
not alter plasma cholesterol and triglyceride levels (not shown).
Consistent with findings that SSR did not cross the blood-brain
barrier, SSR did not impair neurologic performance (not shown).484 Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc.DISCUSSION
We identified a small-molecule multi-FGFR inhibitor that does
not block orthosteric ligand binding and does not act as a classic
FGFR-TKI either. Instead, SSR negatively modulates selected
FGFR signaling pathways with a pharmacologic profile charac-
teristic of an allosteric mechanism.
Targeting the Fibroblast Growth Factor Receptor
Superfamily by SSR
At least two reasons can explain the anti-inflammatory and
anticancer activity of SSR. First, SSR is a multi-FGFR blocker
with a broad action radius. This is necessary to overcome the
substantial redundancy in this superfamily. Blocking a single
FGFR with a monoclonal antibody may be beneficial for cancers
arising from amplification or constitutive activation of a particular
FGFR subtype (Ahmad et al., 2012; Qing et al., 2009; Turner
and Grose, 2010). However, in most cancers, multiple FGFs
are upregulated and various FGFR subtypes on tumor and
stromal cells are activated (Turner and Grose, 2010). In such
conditions, blocking a single FGFR may not suffice to yield
therapeutic benefit. This may be particularly relevant for ECs,
where FGFRs compensate for each other’s loss. Indeed, mice,
Cancer Cell
An Allosteric FGFR Inhibitor Blocks Tumor Growthzebrafish, or tadpoles lacking FGF/FGFRs do not exhibit vessel
defects (Arman et al., 1998; Miller et al., 2000; Reifers et al.,
2000; Zhou et al., 1998). Also, a genetic mouse study docu-
mented redundant roles of FGFRs in coronary vessel formation
(Lavine et al., 2006). Hence, by blocking multiple FGFRs simul-
taneously, SSR not only has a broader action radius, but may
also prevent compensatory rescue by other FGFR members.
A second explanation is that SSR inhibits multiple and diverse
biologic processes that together synergistically fuel inflam-
mation and tumorigenesis. FGFs induce multiple responses in
nearly every cell type in the inflamed or malignant milieu (Mal-
emud, 2007; Pietras et al., 2008). Consistent with findings that
aberrant FGF-signaling stimulates tumor cell proliferation and
migration, and induces epithelial-to-mesenchymal transition of
tumor cells (Billottet et al., 2008; Strutz et al., 2002; Turner and
Grose, 2010), SSR blocked FGF-driven proliferation and migra-
tion of tumor cells in vitro and slowed down tumor growth and
reduced invasiveness and metastasis in vivo. FGFs can also
activate FGFRs on ECs directly or stimulate angiogenesis
indirectly by inducing the release of angiogenic factors from
other cell types (Murakami and Simons, 2008; Presta et al.,
2009). In accordance, SSR reduced FGF-driven EC proliferation,
migration, and capillary tube formation in vitro and tumor angio-
genesis in vivo. But FGFs also stimulate myeloid cells (Berardi
et al., 1995), tumor-associated macrophages (Tsunoda et al.,
2009), cancer-associated fibroblasts (Itoh, 2007; Kharitonenkov,
2009), and osteoclasts (Collin-Osdoby et al., 2002). Consistently,
SSR reduced the accumulation of fibroblasts and myeloid cells
in tumors and osteoclast-mediated breakdown of cartilage in
arthritic joints. Thus, the anticancer/anti-inflammatory potential
of SSR is likely due to a combined effect on many cell types.
Because of the broad repertoire of cellular targets for FGFs,
a multi-FGFR inhibitor like SSR might be expected to be instru-
mental in blocking a wider range of inflammatory and malignant
diseases than analyzed in this study.
A Multi-Fibroblast Growth Factor Receptor Inhibitor
with Allosteric Properties
Several lines of evidence indicate that SSR does not act as
a classic orthosteric inhibitor of FGF binding because it failed
to competitively antagonize binding of FGF2 to FGFRs in
a natural context. SSR also did not act as a classic RTK inhibitor
because it exhibits a hydrophilic partition coefficient, did not
cross the plasma membrane, and failed to block the kinase
activity of FGFR TK domains and a constitutively active TK of
FGFR3 in cells.
Instead, SSR exhibits pharmacologic characterstics of an
allosteric modulator. Mass spectrometry showed that SSR
bound to a site in extracellular D2 or D3 of FGFR2 and failed to
bind to a fragment containing D2 and its adjacent linker, implying
that SSR likely binds a site in D3. Additional biophysical studies
support binding of SSR to D3 (Herbert et al., 2013). Because
D2 and its adjacent linker are critical for orthosteric FGF binding,
the absence of binding of SSR to this fragment provides circum-
stantial evidence that SSR does not interfere with orthosteric
FGF binding. It would be otherwise puzzling to explain how
a small molecule like SSR is capable of inhibiting the responses
of FGFRs to multiple FGF ligands via steric hindrance of the
orthosteric FGFR pocket, given that FGFs are large polypeptidesthat utilize multiple epitopes for interaction with their receptors
(Beenken and Mohammadi, 2009).
Instead, an allosteric mechanism more likely explains how
a small molecule can perturb binding and signaling of a much
larger ligand, and our pharmacologic analyses indicate that
SSR displays typical pharmacologic hallmarks of an allosteric
modulator. For instance, a characteristic of SSR’s allosteric
interactions was the phenomenon of ‘‘probe dependence’’ i.e.,
variations in magnitude and direction of an allosteric interaction
depending on the nature of the orthosteric ligand-receptor
complex with which the modulator is interacting (Christopoulos
and Kenakin, 2002; Litschig et al., 1999; May et al., 2007;
Price et al., 2005). Binding cooperativity was negative in the
SPA with a predimerized Fc-coupled extracellular domain of
FGFR2, while it was neutral in the cellular binding assays to
a naturally folded and signaling-capable FGFR2. An additional
key allosteric feature was the ceiling level (limit) to the degree
of inhibition of FGFR tyrosine phosphorylation and ERK1/2
phosphorylation by SSR at high concentrations, as observed
for other allosteric modulators (May et al., 2007). SSR also
showed a bias toward antagonizing selected FGFR signaling
pathways to the relative exclusion of others. This phenomenon
cannot be explained by a competitive orthosteric mechanism;
if SSR’s mode of antagonism was based on steric hindrance
of FGF ligands, then all pathways should be blocked nondiscri-
minatively to the same extent. Overall, rather than acting as an
allosteric ‘‘affinitymodulator’’, SSR acts as an allosteric ‘‘efficacy
modulator’’ (Conn et al., 2009). The finding that SSR inhibits
FGFR orthologues and paralogues throughout the animal
kingdom suggests that it binds to a conserved allosteric site in
the FGFRs. In the accompanying manuscript (Herbert et al.,
2013), we characterized the molecular mechanisms of the
allosteric properties of the SSR compound.
Possible Implications
From a therapeutic perspective, our studies highlight oppor-
tunities for multi-FGFR inhibitors in arthritis and cancer. An
intriguing question is if SSR might be useful as an anticancer
agent for the treatment of VEGFR-inhibitor-resistant tumors,
given that FGFs belong to a class of ‘‘rescue’’ angiogenic
factors, when tumor-bearing mice or patients are treated with
VEGF inhibitors (Ebos and Kerbel, 2011).
Most anticancer drugs are administered at maximal tolerable
dose to block the target’s activity as maximally as possible.
However, such a strategy may cause adverse effects. Preclinical
studies report that high doses of orthosteric VEGF blockers,
causing high-grade inhibition of VEGF signaling, induce unde-
sired erythrocytosis (Tam et al., 2006) and fuel metastasis
in preclinical models in particular (Ebos and Kerbel, 2011; You
et al., 2011). In contrast, irrespective of its dose, an allosteric
inhibitor has a ceiling effect and cannot completely wipe out
RTK signaling, thus leaving a residual level of baseline signaling
that may suffice to ensure cellular homeostasis and prevent
evocation of undesired responses. Studies of GPCRs and
ion channels show that an allosteric mode of drug-receptor inter-
action offers opportunities for fine-tuning biologic responses in
a manner that is not attainable via classic orthosteric mecha-
nisms (Conn et al., 2009). Finally, from a drug development
perspective, our data offer an incentive to develop orallyCancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc. 485
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an extracellular domain.
EXPERIMENTAL PROCEDURES
Compound Characteristics
Chemical features of SSR128129E are described in the Supplemental
Experimental Procedures. Upon oral treatment of mice with 30 mg/kg,
a maximal plasma concentration (Cmax) of 15.2 ± 0.5 mg/l was achieved at
15 min after treatment. The half-life (T1/2) was 18.4 hr and the area under the
curve at 0–48 hr (AUC0–48hr) was 138.5 mg/hr/l. When rats were treated orally
with 10 mg/kg, the Cmax was 5.3 mg/l, the T1/2 was 5.6 hr, the AUC0–24h was
28.3 mg/hr/l, and the Vss was 1.7 l/kg, and 64% of administered SSR was
available in the plasma. SSR was not detectable in the cerebrospinal fluid,
showing that it was unable to pass through the blood-brain barrier while it
did accumulate in peripheral organs (tissue/plasma ratio for liver is 2–3; for
brain, 0.01).
Binding Experiments
SPA were performed using FGFR1IIIcb/Fc and 125I-FGF2, and cellular binding
assays by using 125I-FGF2 or ELISA. Binding assays listed in Table S1 were
performed by CEREP (Poitiers, France).
Cell Proliferation and Migration Assays
HUVECs, freshly isolated from different donors and used between passage
two and five, were cultured in M199 medium (Invitrogen, Life Technologies,
Ghent, Belgium) supplemented with 20% fetal bovine serum (FBS), 2 mM
L-glutamine, 30 mg/l endothelial cell growth factor supplements (EGCS),
10 units/ml heparin, and penicillin/streptomycin (Lonza, Braine l’Alleud,
Belgium). For proliferation, ECs were starved overnight in growth factor-
depleted M199 medium containing 2% FBS and stimulated for 24 hr with
10 ng/ml bFGF with SSR or DMSO. Proliferation was assessed the last 2 hr
by incubation with 1 mCi/ml [3H]thymidine (Perkin Elmer, Zaventem, Belgium).
Proliferation of porcine aortic endothelial (PAE) and tumor cell lines was
measured using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay
(Promega, Madison, Wisconsin, USA), and cell migration was assessed by a
modified Boyden chamber assay, as detailed in the Supplemental Experi-
mental Procedures. Lamellipodia formation and capillary tube formation was
assessed as described (Mazzone et al., 2009). Each assay was performed in
triplicate and repeated at least three times. B9-FGFR3WT and B9-FGFR3K650E
were obtained from S. Trudel (Toronto, ON, Canada).
Fibroblast Growth Factor Receptor Phosphorylation and Tyrosine
Kinase Assay
Rat fat-pad endothelial (RFPE) cells expressing FGFR1IIIca-hemaglutinin, Sf-9
cells expressing His-tagged Bmbtl, and HEK293 cells expressing FGFR1IIIca,
FGFR2IIIca, or FGFR1IIIcb were stimulated with FGFs in the presence or
absence of SSR. HA-tagged proteins or FGFRs were immunoprecipitated
with an anti-HA-antibody and immunoblotted with HRP-conjugated anti-PY
or HRP-conjugated anti-HA. Kinase activity measurements of the recombinant
catalytic domain of FGFR1 (Sigma-Aldrich, Bornem, Belgium) were done using
the ADP-Glo Kinase Assay (Promega, Madison, Wisconsin, USA).
Mass Spectrometry
Mass spectra using purified FGFR2v23 and FGFR2v2+L were acquired on
a quadrupole orthogonal acceleration time-of-flight mass spectrometer
equipped with standard electrospray source. Sample solutions were prepared
in acetonitrile/water (1/1 v/v) containing 1% (v/v) acetic acid. The electrospray
capillary voltage was 3,000 V and cone voltage 30 V. Nitrogen gas was used
for nebulization and desolvation. Spectra were deconvoluted using the
MaxEnt algorithm.
Animal Experiments
All procedures and care of animals were approved by the Institutional Animal
Care and Research Advisory Committee (KU Leuven, Belgium) and Use
Committees of Sanofi-Synthelabo Recherche (France). All animal experiments
were performed in accordance with the institutional and national guidelines486 Cancer Cell 23, 477–488, April 15, 2013 ª2013 Elsevier Inc.and regulations and are described extensively in the Supplemental Experi-
mental Procedures.
Statistics
All data represent themean ±SEMof the indicated number of experiments.We
used SPSS v.11.0 for statistical calculations. IC50 values were calculated using
Prism v4.0b. Statistical significance was calculated by the indicated test,
considering p < 0.05 as statistically significant.
A more extended version of the materials and methods can be found in the
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2013.02.019.
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